Thank you for Subscribing to Cannabis Business Insights Weekly Brief
David Dodson, Owner and FounderALTVM absorbs that uncertainty of genetic discovery. It has spent over seven years building an operator-driven genetics R&D platform to identify rare cultivars that combine consumer appeal with the performance required by operators. At scale, access to elite genetics that deliver strong yields and consistent laboratory results can make or break operating margins, potentially translating into six- or seven-figure differences in annual profitability. Selections advance through repeated flowering, production, laboratory and retail evaluation, building knowledge around each cultivar. This helps cultivators create more sellable value from licensed growing space, while brands gain proprietary cultivars competitors cannot immediately reproduce. Genetics consulting and phenotype selection further help assess brand fit and commercial performance.
“Our long-term goal is to become the brand behind the brands through elite genetics and scalable selection systems that give operators a unique competitive advantage,” says David Dodson, owner and founder.
Dodson founded ALTVM after nearly a decade cultivating in Michigan, where plant count limits restricted large-population phenotype hunting. Oklahoma’s emerging legal market allowed him to explore genetics at greater scale. When licensed cultivars from a larger multi-state operator yielded and tested below ALTVM’s genetics, he shifted the company from supporting its flower brand toward developing a genetics platform for other brands and operators.
Since then, ALTVM has planted more than 20,000 seeds and created hundreds of original crosses, including Candy Mob, Star World, Hot Ice Cream, Stanky Ass, Blueberry Smash, Sticky Twister, Gyatt Zamn, Groceries and Magic Crystals.
Finding Winning Genetics
ALTVM uses a staged selection process to identify commercially viable cultivars. A typical hunt begins with approximately 1,000 seeds, with one clone taken from each plant around day 21. Seed plants are topped and flowered while clones are preserved. As plants show sex, males and clones are removed unless retained for breeding. Females are assessed for vigor, structure, flower development, disease resistance, flowering time and sexual stability, reducing the population to roughly 250 candidates.
-
Our long-term goal is to become the brand behind the brands by developing elite genetics and scalable selection systems that give commercial operators a unique competitive advantage.
Preserved clones undergo another flowering evaluation. Around 10 to 20 candidates advance to production batches of 30 plants. A cultivar completes at least three flowering rounds before larger production and generally six before entering the portfolio. Fewer than five of every 1,000 seeds typically reach that stage.
For breeding new varieties, ALTVM targets proven performers, complementary traits, portfolio gaps and production challenges. GMO, for example, has strong demand and a recognizable profile but can take more than 10 weeks to flower. ALTVM crossed GMO with a Garlic Breath male, producing Stanky Ass. The cultivar retains 75 percent GMO lineage and finishes in fewer than 60 days.
Validating Genetics
Once cultivars enter commercial production, ALTVM combines cultivation, production, laboratory and retail data to assess performance, finished-product quality and consumer demand. It tracks grams per square foot, potency, terpene content, flowering performance and consistency across runs. Preferred benchmarks include more than 80 grams per square foot, 27 percent total THC and three percent total terpenes, though no single measurement determines whether a cultivar stays in production.
ALTVM also evaluates genetics according to the intended product, recognizing that a plant may wash well for solventless production but produce less finished rosin after pressing, making the final sellable output more meaningful than an intermediate metric. Its on-site dispensary adds validation through sell-through and repeat purchases, showing whether cultivation and product performance translate into demand.
The next stage involves organizing existing intellectual property, continuing R&D and production validation, strengthening cultivar data and finding a strategic partner. ALTVM is open to working with a larger multi-state operator who could provide capital, testing environments, production scale, geographic reach and market data, while ALTVM contributes its genetics pipeline, selection system and operating knowledge.
Developing genetics that perform repeatedly for cultivators, brands, retailers and consumers earns it the title, ‘Top Cannabis Cultivation Solutions 2026’.
Cannabis Genetics That Hold Up Beyond the Trial
Commercial cultivation exposes a costly tension between genetic novelty and repeatable production. A cultivar can look exceptional in a small trial yet lose its appeal when yield or flowering behavior is tested across a larger canopy. Finished-product quality can diverge just as quickly from early promise. Genetics selection, therefore, depends less on finding an interesting plant than on proving that a candidate can survive repeated production without weakening brand distinction. Poor selection at this stage can leave valuable canopies tied to plants that perform inconsistently once trial conditions give way to routine production.
The first buying factor is the depth of the selection process. Large-population searches create access to rare traits, but scale alone means little if weak candidates remain in the pipeline too long. Buyers should examine how early screening is handled, how promising phenotypes are preserved for retesting, how aggressively populations are narrowed and how many flowering rounds occur before commercial release. A disciplined progression from broad populations to smaller production batches lowers the chance that one unusually good plant is mistaken for a repeatable cultivar. It also reveals whether promising traits remain stable after the initial selection environment changes.
Commercial evidence matters just as much as breeding creativity. Early observations can reveal vigor or structure, but they cannot fully predict performance at the production scale. Evaluation should expand once a cultivar moves into larger batches, using canopy productivity, laboratory results, flowering time and consistency across successive runs. Data should also be connected to sell-through and repeat demand once products reach retail. The key is whether the provider distinguishes between exploratory observations and evidence gathered under commercial conditions rather than leaning on isolated test results.
“Once selections reach commercial scale, ALTVM evaluates them through production and laboratory data, retail sell-through and consumer response rather than early plant observations alone.”
Product fit adds another constraint. Genetics intended for premium flower should not be judged by the same endpoint as material bred for extraction. Solventless production creates its own test because a plant can wash well, yet disappoint after pressing. Buyers should look for providers that evaluate genetics against the form in which revenue is actually generated rather than relying on one upstream metric. That requires following a cultivar beyond cultivation performance into the quality and yield of the final sellable product. Development programs that stop earlier risk advancing plants whose apparent strengths do not survive processing.
Exclusivity can materially change the economics of a genetics program. Widely circulated cultivars may simplify sourcing, but they give competing brands access to much of the same starting material. Proprietary selections can create a more defensible identity when the underlying plant also meets production requirements. Buyers should examine how genetic intellectual property is protected, whether exclusivity is available, how development knowledge is retained and whether the provider can support distinct brand requirements without broadly redistributing the same material.
ALTVM develops cultivars through large-population phenotype hunts followed by staged commercial selection. Its process preserves clones from early candidates and advances only a small fraction into production batches. Repeated flowering rounds, then determine whether a cultivar earns a long-term place in the portfolio. Once selections reach commercial scale, ALTVM evaluates them through production and laboratory data, retail sell-through and consumer response rather than early plant observations alone. Its work also extends to genetics consulting and phenotype selection for brand-specific cultivation programs. For buyers who want proprietary genetics tied to repeatable production evidence, ALTVM merits consideration as a cultivation genetics partner rather than a conventional seed supplier.
...Read more
Cannabis Cultivation Solutions Info
Q1
What Do Cannabis Cultivation Solutions Include?
Successful cultivation depends on more than growing conditions. Cannabis Cultivation Solutions cover the genetics, selection methods and evaluation processes used to produce consistent crops with commercial potential. These can include cultivar selection, breeding, flowering performance, laboratory testing and finished-product quality. A promising phenotype still needs to prove itself across repeated production cycles before it merits a larger investment. Growers can compare yield, potency, terpene content, disease resistance and consumer demand to judge whether a variety is worth developing. Looking at these factors together offers a clearer picture of commercial potential than relying on a single attractive trait.
Q2
How Does ALTVM Approach Cannabis Genetics Selection?
Years of cultivation experience in Michigan shaped ALTVM’s approach to genetic research and development. Founded by David Dodson, the company has spent more than seven years refining its selection process. It has planted over 20,000 seeds and created hundreds of original genetic crosses. Rather than stopping at unusual plant characteristics, ALTVM evaluates whether selected cultivars can deliver repeatable results. That distinction matters when cultivation operations need genetics that suit production requirements while giving a product a recognizable identity. Its process connects early genetic selection with the practical demands of growing and evaluating promising varieties.
Q3
Why Is Repeatable Performance Important in Cannabis Cultivation?
A cultivar that performs well in a small trial may behave differently across a larger growing area. Cannabis Cultivation Solutions should account for flowering time, plant structure, disease resistance, yield and finished-product quality. Repeated trials help reveal inconsistencies before a variety takes up substantial growing space. They also separate encouraging early results from performance that holds up over time. Comparing several production runs gives cultivation teams a firmer basis for crop planning, cost decisions and determining which genetic selections deserve further investment.
Q4
Which Factors Matter When Evaluating Cannabis Cultivation Solutions?
The selection process should connect genetic potential with measurable production results. Useful indicators include grams per square foot, total THC, terpene content, flowering time and consistency between runs. Yet no single measure can establish a cultivar’s commercial value. Cannabis Cultivation Solutions should reflect the intended product and the characteristics that matter to its production. Buyers can also examine how candidate plants are screened, preserved for further testing and evaluated before commercial release. Evidence from repeated growing cycles offers a more reliable basis for choosing varieties than early growth observations alone.
Q5
How Do Yield and Product Quality Shape Cultivar Selection?
Yield and quality each show different sides of a cultivar’s potential. For example, genetics meant for solventless extraction need to be judged on more than just how well the plant material washes—the amount of finished rosin matters for its economic value too. Cannabis Cultivation Solutions should consider these differences instead of relying on just one measurement. Lab results can show potency and terpene content, while retail sales and repeat purchases reveal what consumers want. Looking at all these measures helps growers decide if a variety can support a successful product.
Q6
How Does ALTVM Support Distinctive Cultivation Programs?
ALTVM combines genetics consulting with phenotype selection for brand-specific programs. Its process begins with large seed populations, narrows the candidates through repeated flowering evaluations and advances selected plants into production batches. Cultivars generally undergo at least three flowering rounds before larger production, with further evaluation often needed before they enter a portfolio. The company also considers production data, laboratory results and retail response when assessing selected genetics. This approach to Cannabis Cultivation Solutions connects plant selection with commercial performance, allowing distinctive varieties to be evaluated on more than novelty alone.
